Shots:

• The head-to-head Amulet IDE study compares Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the Watchman device to treat patients with AFib at an increased risk of stroke
• The study demonstrated superiority for the 1EPs of LAA (98.9% vs 96.8%) and was non-inferior for the co-primary safety & effectiveness endpoints
• Abbott's Amulet Occluder with dual-seal technology was successfully implanted in 98.4% of patients compared to 96.4% of patients receiving the Watchman device. The device is the first and only minimally invasive option approved for LAA occlusion that does not require blood-thinning medication following implantation

  | Ref: Abbott | Image: Abbott